Qiagen N.v. · NYSE:QGEN
Qiagen — ODDO BHF Forum 2025
59 slides from Qiagen's conference presentation, Jan 9, 2025
Slide 1: Committed to solid profitable growth
Committed to solid profitable growth Investor Introduction Q4 2024
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: The value of biology has never been stronger
The value of biology has never been stronger Crucial to Improving Direct impact advancing healthcare on your science for all lives Q4 2024 Investor Introduction 3
Slide 4: QIAGEN solutions are used across the world
QIAGEN solutions are used across the world by researchers - from young scientists to Nobel laureates - and clinical testing labs Q4 2024 Investor Introduction 4
Slide 5: QIAGEN more focused and stronger than ever
QIAGEN more focused and stronger than ever QIAGEN Life Molecular customers Sciences Diagnostics ~$13-14 bn QIAGEN addressable product Sample technologies market groups ~4-6% (2028) Enhancing PCR CAGR growth and Genomics / NGS ~$11 bn value addressable Diagnostic solutions market (2024) +7% >85% >60,
Slide 6: Well-balanced across key market dimensions
Well-balanced across key market dimensions 2023 net sales: ~$2 bn Diversified product base Strong recurring revenues Global presence Balanced portfolio 12% 16% 34% 32% 36% Product Product 47% Regions Customers 53% groups types 3% 15% 88% 52% 12% Sample technologies Consumables and related revenues A
Slide 7: Delivering solid growth since 2019
Delivering solid growth since 2019 Strong non-COVID growth Improved profitability Healthy cash generation Total net sales Adjusted diluted EPS Operating cash flow +7% +10% +9% CAGR(1) CAGR CAGR ~$2.0 bn $2.07 ~$460 mn ~$1.5 bn ~$330 mn $1.43 2019 2023 2019 2023 2019 2023 (1) Non-COVID sales CAGR 201
Slide 8: Strong global presence in developed and emerging markets
Strong global presence in developed and emerging markets Our global and regional headquarters Direct sales in >30 countries Shipping products to >170 countries Germantown Venlo Hilden Maryland Netherlands Germany Singapore Shanghai Americas HQ Global HQ EMEA HQ Asia-Pacific HQ China HQ Q4 2024 Inves
Slide 9: From academia to clinical labs, continuum of differentiated solutions
From academia to clinical labs, continuum of differentiated solutions Samples Sample preparation Detection Insights PCR Any Sample Genomics / NGS biological technologies sample Diagnostic solutions Life Sciences customers Molecular Diagnostics customers Academic labs Hospitals / Decentralized health
Slide 10: Strategy: Committed to solid profitable growth
Strategy: Committed to solid profitable growth Our 2028 targets Sharpen focus on growth pillars to At least $2 bn sustain profitable growth net sales CER from pillars in 2028 ~7% At least 250 bps Net sales CER CAGR Drive efficiency and digitization to fuel (2024-28) growth investments and profitabil
Slide 11: Focusing on attractive opportunities
Focusing on attractive opportunities Product PCR / Nucleic acid Sample technologies Diagnostic solutions NGS / Genomics groups amplification 2023 sales ~$663 m ~$698 m ~$300 m ~$239 m Accelerate investments for growth Build on proven leadership QIAcuity #2 QIAstat-Dx #3 QIAGEN #1 Sample #1 QuantiFER
Slide 12: QIAcuity dPCR
QIAcuity dPCR Quantitative PCR QIAcuity dPCR Next-generation (qPCR) Enabling novel applications sequencing (NGS) e.g., Cell and Gene Therapy e.g., liquid biopsy Lower sensitivity High sensitivity and precision In-depth insights and precision More accurate than qPCR and high precision dPCR – Capturin
Slide 13: Targeting research to clinical healthcare
Targeting research to clinical healthcare Key achievements Scalable systems Low- to high- throughput capabilities QIAcuity One QIAcuity Four QIAcuity Eight >2,000 cumulative placements since launch Academia Overcoming entry barrier vs. qPCR Translational and Ease of use Fully integrated cancer resea
Slide 14: Significant investments into QIAcuity dPCR
Significant investments into QIAcuity dPCR ≥$250 mn QIAcuity net sales CER target (2028) Target Extend Accelerate commercialization new applications into clinical use >3x increase NEW Add >100 assays NEW QIAcuity-Dx NEW of sales specialists for market menu expansion for CGT, version for Launch 2024
Slide 15: QIAstat-Dx
QIAstat-Dx Use case: 3-year-old with severe but unspecific GI symptoms Traditional testing Syndromic testing Slow diagnosis and treatment Fast diagnosis enabling better decisions can lead to complexities treatment decisions Identifying unknown diseases at speed and ease Day 1 Day 1 One test within o
Slide 16: QIAstat-Dx offers differentiated features
QIAstat-Dx offers differentiated features Key achievements Strong product capabilities Key differentiators Specification QIAstat-Dx Competition Workflow Additional >4,000 cumulative placements efficiency pathogens since launch Hands-on time ~1 min >5 min and safety on panels for for broader robust r
Slide 17: Expanding global presence and differentiated menu
Expanding global presence and differentiated menu ≥$200 mn QIAstat-Dx net sales CER target (2028) Grow installed Small hospitals Medium hospitals Large hospital networks customer Public health labs Regional reference labs National reference labs base FDA submission 2024 Low-throughput High-throughpu
Slide 18: QIAGEN Digital Insights unlocking the power of genomics
QIAGEN Digital QIAGEN unlocking the power of genomics Insights Development Genomic data In 2003, the first Today, any human human genome took genome can be read in 13 years 5 hours Sequencing Powerful analytics costs $100 / to understand >$1 bn / genome sequencing run 2000 2010 2020 2030 genomics Th
Slide 19: #1 leading from research to clinical customers
#1 leading from research to clinical customers Key achievements Addressing large customer base Delivering QDI software solutions for NGS workflow #1 Research – in bioinformatics software for research and clinical Scientific discovery Pharma / Biotech Academia Government research Sample prep Library
Slide 20: Case study: Research Advancing drug development
Case study: Research Advancing drug development Pharma challenge QDI pivotal to drug discovery Over 50,000 scientific publications cite our software Key to understanding disease pathways, targets and measure changes 24 of the Top 25 Pharma companies use QDI Significant number of failures without the
Slide 21: Case study: Clinical Enhancing patient outcomes
Case study: Clinical Enhancing patient outcomes Patient situation QDI-enhanced patient outcome Mutation identification and recommendation by QDI Profile Male (early 70s) Targeted therapy leading to life-saving disease remission Diagnosis QIAGEN Clinical Leukemia linked to rare gene mutation Insights
Slide 22: QIAGEN Offering uniquely profitable software-as-a-service
QIAGEN Offering uniquely profitable software-as-a-service Digital portfolio Insights Data analysis Data interpretation ~$100 mn Research Share of net sales QIAGEN CLC #1 QIAGEN IPA #1 QDI net sales (2023) ~60% OmicSoft #1 COSMIC #1 Human Gene Mutation #1 >80% annual recurring from subscription-based
Slide 23: Investing to extend market leadership
Investing to extend market leadership ≥$200 mn QDI net sales CER target (2028) Extend leadership in curated Deepen global Invest in new AI and other knowledge commercial reach technologies Expand QIAGEN knowledge base into Adopt SaaS go-to-market NEW Continue advancing software NEW spatial, proteomi
Slide 24: Sample technologies
Sample technologies Laboratory workflow Differentiated solutions for PCR Valuable Biological Sample modular, integrated workflows molecular sample technologies insights Fast time to result, scalability Critical step in and ease of use dPCR High-quality molecular sample prep key to workflows Platform
Slide 25: Leader in the first step of lab workflows
Leader in the first step of lab workflows Key achievements Comprehensive Any >350 DNA / RNA consumables portfolio biological sample different sample kits target analytes >120 mn QIAGEN preparations e.g., tissue, cells, blood, for manual and sold per year including variations serum, wastewater automa
Slide 26: Extending comprehensive automation offering
Extending comprehensive automation offering >14,400 placements(1) Benchtop system Launch 2026 NEW Research / applied QIAcube Validated and customized protocols QIAsprint testing Connect Connect Up to 12 samples per run Up to 192 samples per run Large menu supporting applications Low-throughput Mid-t
Slide 27: Focused strategy to drive mid-term growth
Focused strategy to drive mid-term growth ≥$750 mn Sample technologies Liquid Pathogen net sales CER target Expand in state-of-the-art Microbiome biopsy detection (2028) applications with new consumables Extend #1 position with improved handling through new consumables kits Enter high-throughput QIA
Slide 28: QuantiFERON Tuberculosis: A highly contagious and lethal bacterial infection
QuantiFERON Tuberculosis: A highly contagious and lethal bacterial infection 1 in 4 Broad health risk Global relevance people have a latent TB bacterial infection High risk of ssion to active ogre TB pr 1 in 10 EMEA of these people will develop an Immunocompromised ~10 mn active TB bacterial infecti
Slide 29: Best-positioned latent tuberculosis test
Best-positioned latent tuberculosis test QuantiFERON Tuberculin Key achievements Advantages to Specification blood test skin test skin test Customizable automated workflow High accuracy and specificity $408 mn 2023 net sales (+70% vs. 2019) Only one patient visit Electronic results Quality-assured l
Slide 30: Driving skin test conversion with unrivaled automation
Driving skin test conversion with unrivaled automation ≥$600 mn QuantiFERON Leading automation advantage net sales CER target (2028) Automated Automated Increase liquid handling assay and result customer base Partnership with Diasorin to expand into Lyme disease Large potential in skin test conversi
Slide 31: Initiatives to fuel growth investments and achieve ≥31% adjusted operating income margin
Initiatives to fuel growth investments and achieve ≥31% adjusted operating income margin in 2028 Operational excellence Digitization Positioning QIAGEN for stronger profitable growth Accelerating growth and efficiency across QIAGEN Organizational design Portfolio streamlining >6 million ~30 website
Slide 32: Executing our strategy with empowered QIAGENers
Executing our strategy with empowered QIAGENers Great Great Great Great Great Great Place Place Place Place Place Place ~6,000 To Work Certified ® NOV 2023–NOV 2024 USA To Work ® Certificada DEC 2022–DEC 2023 MEXICO To Work Certificada ® OCT 2023–OCT 2024 BRASIL To Work Certified ® NOV 2021–NOV 2022
Slide 33: Embracing ESG for all stakeholders
Embracing ESG for all stakeholders Top ESG ratings Environmental responsibility Net zero carbon emission target (2050) Investing in people 36% female leadership (2023) ≥40% target (2027) Serving society >50 public health partnerships (2023) Business with integrity ~8,000 compliance trainings complet
Slide 34: Leveraging strong balance sheet and cash flows to enhance growth
Leveraging strong balance sheet and cash flows to enhance growth Organic Profitable targeted investments investments into pillars and digitization to fuel profitable business expansion Strong cash flow and healthy Focused Value-creating transactions M&A to enhance portfolio and maintain leadership b
Slide 35: Reinvigorated leadership team dedicated to deliver
Reinvigorated leadership team dedicated to deliver Supervisory Board Executive Committee Lawrence A. Rosen Metin Colpan Chair Co-founder of QIAGEN Thierry Bernard Roland Sackers Joined in 2013 Chief Executive Officer Chief Financial Officer Joined EC in 2015 Joined EC in 2004 Toralf Haag Ross Levine
Slide 36: Why invest: Commitment to solid profitable growth
Why invest: Commitment to solid profitable growth Why invest in QIAGEN Trusted high-quality Differentiated portfolio Specialist sales force >85% highly brand with strong in fast-growing market backed by extensive recurring revenues customer networks segments digital engagement Accelerate Net sales M
Slide 37: Q3 2024 results
Q3 2024 results Exceeded outlook for net sales and adjusted EPS November 6, 2024
Slide 38: Q3 2024: Exceeded outlook for net sales and adjusted EPS
Q3 2024: Exceeded outlook for net sales and adjusted EPS Growth $502 m ($502 m CER) Q3 2024: Solid sales growth trends across portfolio Net sales • +6% CER growth and +6% CER excluding NeuMoDx +6% CER • Diagnostic solutions (+10% CER), Sample technologies (+1% CER) vs. Q3 2023 and PCR / Nucleic acid
Slide 39: Q3 2024: Sales performance and key developments
Q3 2024: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) +6% Sample • Solid sales growth from automated consumables CER(1) technologies • Encouraging instrument placement rates 476 502 • +10% CER growth, sixth consecutive quarter above $
Slide 40: Q3 2024: Strong quarter for operating profitability
Q3 2024: Strong quarter for operating profitability Adj. operating income margin Adj. EPS ahead of Q3 2024 outlook Adj. +18% to $149 million on efficiency operating gains and NeuMoDx benefits +3 ppt 29.6% income 26.6% Non- 20% adj. tax rate above estimate operating for ~19% income $0.57 Adj. EPS(1)
Slide 41: Q3 2024: Significant improvement in cash flow generation
Q3 2024: Significant improvement in cash flow generation Cash flow Debt maturity overview(1) (in $ millions) In $ millions Q3 2024 Q3 2023 Change Operating cash flow 182 125 +46% 619 Purchases of PP&E - 43 -36 +22% 500 119 500 Free cash flow 139 89 +56% Likely repayment in 2025(2) 500 157 In $ milli
Slide 42: Q3 2024: Portfolio developments
Q3 2024: Portfolio developments Sample technologies: QIAcuityDx: HID / Forensics: Advancing liquid biopsy with innovation Harnessing the power of digital PCR Tracing roots, preserving identities Novel urine liquid biopsy solution Moving into clinical diagnostics Partnerships driving NGS adoption in
Slide 43: QIAstat-Dx: Four U.S. clearances in 2024 to accelerate growth
QIAstat-Dx: Four U.S. clearances in 2024 to accelerate growth Complete Panels Mini Panels Precision Medicine 3 Respiratory IVDR 2024 NEW(1) Respiratory(2) 2024 NEW Pharma partnerships Gastro IVDR 2024 NEW Gastro(3) 2024 Chronic diseases NEW Meningitis 2024 NEW Alzheimer's disease Instruments Blood c
Slide 44: 2024: Outlook perspectives
2024: Outlook perspectives Reaffirming net sales outlook Increasing adj. EPS outlook + ~$0.09 Full-year 2024 + ~$0.06 outlook update ≥$1.985 bn ≥$2.19 CER + ~$0.04 CER $1.965 bn ≥$2.16 Reaffirming net sales $25 m ≥$2.14 CER ≥$2.10 CER $42 m ≥$2.07 CER ≥$1.985 bn CER Increasing adj. diluted EPS ≥$2.1
Slide 45: 2024: Updating full-year outlook
2024: Updating full-year outlook As of November 6, 2024 Q4 2024 outlook FY 2024 outlook Net sales >$520 million CER >$1.985 billion CER Anticipated currency impact No currency impact Adverse impact of ~ -1 ppt Adjusted diluted EPS >$0.60 CER >$2.19 CER Anticipated currency impact No currency impact
Slide 46: Appendix
QIAGEN Appendix
Slide 47: Q4 and FY 2024: Outlook and assumptions
Q4 and FY 2024: Outlook and assumptions (As of November 6, 2024) Q4 2024 outlook FY 2024 outlook Net sales >$520 million CER >$1.985 billion CER Anticipated currency impact(1) No currency impact Adverse impact of ~ -1 ppt Adjusted diluted EPS(2) >$0.60 CER >$2.19 CER Anticipated currency impact(1) N
Slide 48: Q3 2024: Consolidated Statements of Income (unaudited)
Q3 2024: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended September 30, 2024 September 30, 2023 Net sales 501,869 475,894 Cost of sales: Cost of sales 179,817 161,864 Acquisition-related intangible amortization 13,745 16,070 Tota
Slide 49: 9M 2024: Consolidated Statements of Income (unaudited)
9M 2024: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Nine months ended Nine months ended September 30, 2024 September 30, 2023 Net sales 1,457,012 1,456,149 Cost of sales: Cost of sales 777,922 490,407 Acquisition-related intangible amortization 45,030 48,154 To
Slide 50: 2024: Quarterly sales by product group
2024: Quarterly sales by product group Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 155 -11% -10% 164 -1% 1% 162 1% 1% 480 -4% -3% Diagnostic soluti
Slide 51: 2024: Quarterly sales by product type, customer class and region
2024: Quarterly sales by product type, customer class and region Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 409 -5% -4% 442 2% 3%
Slide 52: Q3 and 9M 2024: Reconciliation to adjusted results (unaudited)
Q3 and 9M 2024: Reconciliation to adjusted results (unaudited) Operating Pre-tax Net Net Gross Income Tax Diluted (In $ millions, except EPS) income income income sales profit tax rate EPS* (loss) (loss) (loss) Third quarter 2024 Reported results 501.9 308.3 112.1 116.5 (18.4) 16% 98.1 0.44 Adjustme
Slide 53: Q3 and 9M 2024: Footnotes for reconciliation to adjusted results
Q3 and 9M 2024: Footnotes for reconciliation to adjusted results (unaudited) a. Results for 2024 include charges for the restructuring program initiated in Q2 2024, as well as acquisition projects, including the continued integration activities at Verogen Inc. b. Cash Convertible Notes were recorded
Slide 54: 2024: Quarterly income statement summary
2024: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Net sales 458.8 496.3 501.9 1,457.0 Net sales (CER) 461.7 502.0 502.2 1,465.9 Gross profit 291.0 34.8 308.3 634.1 Gross profit margin 63.4% 7.0% 61.4% 43.5%
Slide 55: Consolidated Balance Sheets
Consolidated Balance Sheets September 30, December 31, September 30, December 31, (In $ thousands, except par value) 2024 2023 (In $ thousands, except par value) 2024 2023 Assets (unaudited) Liabilities and Equity (unaudited) Cash and cash equivalents 972,985 668,084 Current portion of long-term deb
Slide 56: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Nine months ended September 30, September 30, Nine months ended September 30, September 30, (In $ thousands) 2024 2023 (In $ thousands) 2024 2023 Cash flows from operating activities: Cash flows from financing activities: Net (loss) income (4,731) 24
Slide 57: Q3 and 9M 2024: Currency impact
Q3 and 9M 2024: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q3 2024 U.S. dollar 278.4 278.5 56% 0.1 Euro 93.3 92.4 18% -0.9 British pound 21.1 20.7 4% -0.4 Japanese yen 10.4 10.6 2% 0.2 Other currencies 98.6 99.9 20%
Slide 58: Employees as of September 30, 2024
Employees as of September 30, 2024 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q3 2024 Q2 2024 Change Production 379 1,168 137 1,684 1,701 -1% R&D 213 769 57 1,039 1,053 -1% Sales 565 845 739 2,149 2,162 -1% Marketing 66 194 67 327 332 -2% Administration 80 419 159
Slide 59: Your contacts
Your contacts Dr. Domenica Martorana Associate Director Calendar Global Investor Relations Deep Dive: QDI December 2024 Phone: +49 2103 29 11244 E-mail: domenica.martorana@qiagen.com Q4 and FY 2024 results February 2025 Q1 2025 results May 2025 Alexandra Koenig Coordinator Share information Investor